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Bryostatin 1 is a naturally occurring macrocyclic lactone derived
from the marine invertebrate Bugula neritina (Pettit et al, 1982). It
is a partial agonist of protein kinase C (PKC), a multigene family
of isoenzymes with serine-threonine kinase activity that are crucial
in cellular signalling pathways and influence proliferation and
differentiation (Nishizuka, 1986). Bryostatin 1 induces differentia-
tion of non-Hodgkin’s lymphoma cell lines (Mohammed et al,
1993) and has antitumour activity against a variety of human and
murine cell lines in vitro in addition to murine models of L10A B
cell lymphoma in vivo (Pettit et al, 1982; Hornung et al, 1992).
The exact mechanism of action of bryostatin 1 is unclear. It is
known that an initial cellular effect is activation and translocation
of PKC followed by its down regulation (Berkow et al, 1993). The
antitumour effects of bryostatin 1 in vivo may in part be due to
immunomodulatory function. For example, the expansion of
myeloid and erythroid progenitor cells stimulated by the cytokines
GM-CSF, M-CSF and IL-3 is amplified in the presence of 
bryostatin 1 (May et al, 1987; Sharkis et al, 1990). Similarly,
peripheral blood mononuclear cells derived from cancer patients
following intravenous infusion of bryostatin 1 have been shown to
exhibit enhanced lymphokine activated killer cell activity and
proliferation when stimulated by interleukin-2 (Scheid et al, 1994;
Jayson et al, 1995). However bryostatin 1 also inhibits production
of members of the matrix metalloproteinase family thought to be
essential for angiogenesis and metastasis (Wojtowicz-Praga et al,
1997), down-regulates MDR1 gene expression (Al-Katib et al,
1998), modulates bcl-2 and p53 gene expression (Maki et al, 1995)
and induces apoptosis (Mohammed et al, 1995) in models of
human diffuse large cell lymphoma. 
During phase I clinical evaluation of bryostatin 1 antitumour
activity was observed in metastatic melanoma (Philip et al, 1993),
ovarian cancer and low grade non-Hodgkin’s lymphoma (Jayson et
al, 1995). The dose-limiting toxicity (DLT) was myalgia and
despite several investigations into the aetiology no effective anti-
dote or treatment has been determined for this to date (Hickman 
et al, 1995; Thompson et al, 1996). Phlebitis was also a significant
toxicity and initially attributed to the 60% ethanol formulation used
for administration (Prendiville et al, 1993). The subsequent use of a
PET formulation (10 mg bryostatin ml–1 of 60% polyethylene
glycol, 30% ethanol, 10% Tween 80) reduced the incidence of
phlebitis (Philip et al, 1993). From these studies a maximum toler-
ated dose (MTD) of 25 mg/m2 bryostatin 1 administered by infusion
over one hour, weekly, for 3 weeks out of 4 (Philip et al, 1993), or
over 24 hours once weekly (Jayson et al, 1995) was established. On
the basis of the aforementioned preclinical and phase I data we
undertook a phase II study to determine the efficacy of bryostatin 1
in patients with progressive NHL of indolent type. 
MATERIALS AND METHODS 
Patients 
Patients eligible for inclusion were aged 18 or over with histologic-
ally proven NHL of indolent type, bi-dimensionally measurable
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and progressive disease. Patients could have received a maximum
of two prior multi-drug chemotherapy regimens. Biopsy at relapse
was recommended since the histological grade of NHL can change
over time. Histological subtye was classified according to the
updated Kiel Classification (Stansfeld et al, 1988). Patients were
required to have a WHO performance status of 0–2, a life
expectancy of greater than 3 months, a neutrophil count equal to or
greater than 1.5 ´ 109 l–1, platelets equal to or greater than 100 ´
109 l–1, serum transaminases less than 2.5 ´ upper limit of normal,
serum bilirubin less than or equal to 20 mM, serum creatinine less
than or equal to 120 mM and no toxic manifestations of previous
treatment except alopecia. Patients were excluded if they had
severe or uncontrolled non-malignant systemic disease, active
infection, previous or existing CNS disease, previous or concur-
rent malignancies except in situ carcinoma of the cervix or
adequately treated basal or squamous cell carcinoma of the skin, 
if pregnant or lactating and if unable to give written informed
consent. Concomitant treatment with systemic steroids was not
permitted. The study was approved by the Phase I/II Committee
and Central Institutional Review Board of the Cancer Research
Campaign, the National Cancer Institute, Local Regional Ethics
Committees and conducted according to the Declaration of
Helsinki. Written informed consent was obtained in all patients.
The use of bryostatin had UK Medicines Control Agency
approval. 
Drug dose and administration 
Bryostatin 1 (US National Cancer Institute, Arizona State
University/ Cancer Research Institute, USA) was stored at 4˚C in
vials containing 0.1 mg of lyophilized powder. For administration
the lyophilized powder was dissolved in 1 ml of polyethylene
glycol 400, ethanol and Tween 80 (PET, 60/30/10 v/v) then further
diluted with 0.9% sodium chloride to give a solution containing
10 mg ml–1 of bryostatin. This primary solution was further diluted
by coinfusion with 1–2 litres of 0.9% saline over 24 hours through
a peripheral venous catheter with the infusion rate of bryostatin
controlled by a syringe pump. 10 ml polypropylene plastic syringes
(SIMS Deltec Inc St Paul, MN, USA) and polyfin extension sets
(model 126, Minimed Technologies, CA, USA) were used. 
Assessment of toxicity 
Investigations performed before commencing therapy included a
bone marrow trephine biopsy, full blood count with a differential
white cell count, serum biochemistry, urinalysis and chest radio-
graph. Patients were reviewed by a physician weekly to record
new signs and symptoms and document performance status
(WHO). A full blood count with differential white cell count and
serum biochemistry were repeated weekly. Additional investiga-
tions were performed as appropriate. National Cancer Institute of
Canada Clinical Trials Group (NCIC-CTG) expanded common
toxicity criteria were used to grade adverse events except for
myalgia, which was graded according to the scale described by
Philip et al (1993). 
Assessment of tumour response 
Evaluable and measurable disease sites were assessed before 
treatment by physical examination, plain radiography and comput-
erized tomography. Physical examination was repeated weekly and
imaging investigations to determine tumour measurements were
repeated monthly or at the time of suspected disease progression.
Standard WHO criteria for assessment of objective responses were
employed (Miller et al, 1981). Patients with progressive disease
were withdrawn from the study. Patients were considered evaluable
for response if they received 3 or more infusions of bryostatin. 
Statistics 
To ensure a low probability (P < 0.05) of erroneously rejecting a
treatment that is active in 20% of patients, a minimum of 14 evalu-
able patients were treated according to previously described 
principles (Gehan, 1961). 
Bryostatin adsorption studies 
The extent of adsorption of bryostatin 1 onto the plastics used was
examined. The materials examined were 10 ml polypropylene
syringe (SIMS Deltec Inc, St Paul, MN, USA), polyfin extensions
sets (MiniMed Technologies, Sylmar, CA, USA) and central
venous catheter (Broviac 6.6 Fr single lumen, Bard Ltd, Crawley,
UK). Bryostatin 1 solutions were prepared exactly as for clinical
drug administration at 10/mg ml and a typical 40 mg dose of bry-
ostatin 1 was used to fill the infusion devices. Following storage at
room temperature in standard lighting samples were withdrawn
and analysed by UV-HPLC at time points up to 7 days after filling
according to previously published methodology (Khan et al,
1998). Concentrations of bryostatin 1 were determined by use of
standard curves run immediately before the samples. All plastics
were tested in duplicate and duplicate drawn samples from each
set were analysed. 
RESULTS 
Patients 
17 patients (10 men, 7 women: age range 39–77 years, median 56,
mean 58) with NHL were recruited. 16 patients had previously
received chemotherapy including an alkylating agent (≤ 2 single
drug regimens; n = 6: ≤2 multidrug regimens ± ³1 single drug
regimen; n = 9: >2 multidrug regimens; n = 1). 7 patients had also
received prior radiotherapy, 3 patients had also received biological
therapy (vitamin D and/or interferon) and 1 patient had received
PUVA therapy. Re-biopsy evidence of low-grade NHL was
obtained in 14 patients and all had documented disease progres-
sion within 2 months prior to entry to the study. Their characteris-
tics are summarized in Table 1. 
Response to treatment 
Of 17 patients treated, 14 were evaluable for response. Of those
who were not evaluable, 2 patients received less than 3 infusions
and 1 patient had received more than 2 previous multidrug regi-
mens. The median number of bryostatin 1 infusions given per
patient was 6 (range 1–9) and 7 patients received 8 or more infu-
sions. The outcomes of treatment are summarized in Table 2. No
responses (complete or partial) were seen although there were
mixed responses in 6 patients with some lesions undergoing
shrinkage and others progressing. In one patient disease stabiliza-
tion was for 9 months. This patient declined further treatment after
8 infusions in order to return to work. Toxicity 
All patients were included in the analysis of toxicity (Table 3). The
main toxicities were myalgia (n = 8) and phlebitis (n = 13). A one
week treatment delay and dose reduction (25%) of bryostatin 1 in
one patient who had grade 3 myalgia prevented subsequent
episodes. The median number of bryostatin infusions given prior
to onset of myalgia and phlebitis was 2 (range 1–9) and 1 (range
1–4), respectively. Treatment was withdrawn in 4 patients due to
phlebitis. In one patient bryostatin 1 was discontinued after 5 infu-
sions due to grade 2 thrombocytopenia which was possibly treat-
ment related. 
Bryostatin adsorption studies 
Bryostatin 1 was assayed by our previously published method
(Khan et al, 1998). No visible colour changes or precipitate formed
upon storage for up to 7 days. There were no additional or apparent
decomposition peaks as assessed by HPLC profiles. Adsorption to
the polypropylene infusion device, extension set and central
venous catheter was very low at 24 hours and upon storage for 7
days there was greater but limited adsorption to the infusion device
(Figure 1). This adsorption data is similar to that reported by others
(Cheung et al, 1998). It should be noted that PVC shows signifi-
cant adsorptive properties (Cheung et al, 1998) and our own
preliminary work suggests that ethyl vinyl acetate also adsorbs
bryostatin 1 (AT McGown, M Ranson, unpublished observations). 
DISCUSSION 
In this phase II study 17 patients with progressive NHL, previ-
ously treated with chemotherapy, received a median of 6 (range
1–9) intravenous 24 hour infusions of 25 mg/m2 bryostatin 1, given
once weekly. 7 patients completed 8 or more infusions. No
responses were observed although stable disease was attained in
one patient for 9 months. The majority (11/17) of patients were
withdrawn from the study because of disease progression and in 5
patients this occurred before 8 infusions of bryostatin 1 had been
administered. 
The reason for lack of efficacy despite promising preclinical and
phase I data, is unclear. Phase II studies of bryostatin 1 given at the
same dose but with a one hour infusion in patients with malignant
melanoma have also failed to demonstrate significant antitumour
activity (Propper et al, 1998; Gonzalez et al, 1999). In contrast, in
a phase I trial Varterasian et al (1998) achieved a higher MTD,
again limited by myalgia, of 120 mg/m2 bryostatin 1, infused over
72 hours every 2 weeks. A phase II trial of this regimen was
recently reported documenting one complete remission of 18
months and two partial remissions of greater than 6 months dura-
tion in patients with low grade NHL (Varterasian et al, 2000). Lack
of efficacy of bryostatin 1 in the current study may therefore be
due to suboptimal dose and duration of treatment but antitumour
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Table 1 Patient characteristics (n = 17) 
Parameter No. of patients 
Sex
F7  
M 10 
Age median = 56 years (range 39–77) 
WHO performance status 
01 1  
15  
21  
30  
40  
Disease sites 
Nodal 13 
Nodal and skin 1 
Nodal and pleural 1 
Nodal and liver 1 
Skin 1 
Bone marrow involvement 13 
Histology 
Follicular 7 
Small lymphocytic 4 
Other indolent B cell types 6 
Previous chemotherapy 
Alkylating agent 16 
Anthracycline 4 
Table 2 Outcome of treatment with bryostatin (n=17) 
Patient Number of infusions (weeks on treatment) Reason off study Response 
1 5 (6**) PD PD 
2 6 (6) Toxicity (phlebitis + myalgia) + PD PD* 
3 4 (4) Toxicity (phlebitis + myalgia) + PD PD 
4 6 (7**) PD PD 
5 8 (8) PD PD 
6 5 (5) Toxicity (thrombocytopenia) + PD PD* 
7 2 (2) PD Not evaluable 
8 8 (8) PD PD 
9 9 (10**) PD PD 
10 3 (3) PD PD 
11 8 (8) PD PD 
12 1 (1) Toxicity (phlebitis) Not evaluable 
13 5 (5) Toxicity (phlebitis) Not evaluable 
14 9 (11**) PD PD 
15 8 (8) Declined further treatment Stable disease 
16 8 (9**) PD PD 
17 3 (4**) PD PD 
*Clinical evidence of disease progression, objective measurements were not evaluable. **Patients in whom treatment
delays occurred. PD = progressive disease. 468 FH Blackhall et al  
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activity was observed during phase I evaluation using both 1
and 24 hour infusions of 25 mg/m2 bryostatin 1 (Philips et al,
1993; Jayson et al, 1995). As there is no established method 
to reliably determine serum concentrations of bryostatin 1 in
humans it has not been possible to obtain pharmacokinetic data to
determine serum concentrations and rationally optimize the
schedule. Animal data suggest that bryostatin 1 has a short plasma
half life (Berkow et al, 1993) with in vitro and in vivo data
showing enhanced antitumour effects on prolonged exposure
(Hornung et al, 1992) and the data of Varterasian et al would
support this. However, it is perplexing that significant differences
in MTD of bryostatin 1 have been demonstrated despite consensus
regarding toxicity. In addition to the aforementioned studies a
MTD of 44 mg/m2 bryostatin 1 administered over 1 hour weekly
for 3 weeks out of 4 has been reported in a paediatric oncology
group study (Weitman et al, 1999). The significant adsorption of
bryostatin 1 onto polyvinyl chloride and ethyl vinyl acetate
(Cheung et al, 1998) raises the possibility that differences in
adsorptive properties of administration devices used may account
for discrepancies in MTD observed. Compared with other studies,
phlebitis was a significant toxicity in this study. We chose a
peripheral vein for drug administration due to uncertainty over the
adsorption of bryostatin onto material used for central infusion
devices but have subsequently demonstrated that the adsorption of
bryostatin onto small (10 ml) polypropylene infusion devices and
a central infusion catheter is negligible over 24 hours (Figure 1).
Central administration may therefore be safely used to avoid
phlebitis; however materials used for infusion of bryostatin 1
should be clearly stated in all reports of clinical trials. 
Further explanations for lack of efficacy of bryostatin 1 in this
study include suppressed lymphocyte function due to lymphoma
or previous chemotherapy and radiotherapy which may have
prevented bryostatin 1 from acting through immune stimulatory
mechanisms (Propper et al, 1998). In addition the modulation of
tumour-specific PKC isoenzyme profiles by bryostatin 1 is poorly
understood. PKC isoenzymes are involved in both oncogene and
tumour suppressor gene activation, variable expression of PKC
isotypes in tumours has been demonstrated and the degree to
which isotypes are downregulated by bryostatin 1 also varies
(Buchner, 2000). Bryostatin 1 may only be effective when targeted
to individuals bearing tumours with particular PKC isoenzyme
profiles. 
The efficacy of bryostatin 1 may be enhanced by administration
in combination. For example, pretreatment with bryostatin 1
increases the cytotoxicity of 2-chlorodeoxyadenosine in drug-
resistant chronic lymphocytic leukaemia cells (Mohammed et al,
1998), cisplatin in human cervical carcinoma cells (Basu and
Lazo, 1992) and cytarabine in fresh blast cells from patients with
acute myeloid leukaemia (Elgie et al, 1998). In a tumour-bearing
mouse model enhanced cytotoxicity is observed when bryostatin 1
is administered following paclitaxel (Koutcher et al, 2000);
synergy between bryostatin 1 and tamoxifen, which also inhibits
PKC, has been demonstrated in the drug resistant P388 leukaemia
cell line which lacks steroid receptors (McGown et al, 1998) and
vincristine in combination with bryostatin 1 has been shown to
cure mice bearing xenografts of neoplastic B cells derived from
human Waldenströms macroglobulinaemia (Mohammed et al,
1994). On this basis, Varterasian et al (2000) conducted a feasi-
bility study in which patients who developed progressive NHL
while receiving single agent bryostatin were given sequential
treatment with vincristine. Doses of up to 2 mg/m2 vincristine
were well tolerated with no unexpected or enhanced toxicity.
Similarly, in early reports of phase I trials, bryostatin 1 in combi-
nation with paclitaxel or cisplatin appears to be well tolerated and
myalgia has occured less frequently than in single agent trials
(Kaubisch et al, 1999; Rosenthal et al, 1999). 
In summary, this study failed to show a significant benefit from
single agent bryostatin 1 in progressive NHL of indolent type.
Improved understanding of bryostatin 1 pharmacokinetics and
Table 3 Toxicities associated with bryostatin treatment (n = 17) 
Number of patients 
NCIC – CTG Grade* 0 1 2 3 4 
Myalgia** 9 4 3 1 0 
Phlebitis 4 1 10 2 0 
Headache 14 3 0 0 0 
Fatigue 12 5 0 0 0 
Nausea/vomiting 13 4 0 0 0 
Diarrhoea 16 1 0 0 0 
Thrombocytopenia 15 1 1 0 0 
Leucopenia 15 2 0 0 0 
Bilirubin 16 0 0 1 0 
Neuralgia 16 1 0 0 0 
*National Cancer Institute of Canada Clinical Trials Group expanded toxicity
scale. **Graded according to Philip et al (1993). 
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modulation of tumour PKC isotypes by bryostatin 1 would prob-
ably aid development of this novel agent. Further evaluation of
bryostatin 1 in combination is warranted. 
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